The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
The companies aim to expand treatment options for millions living with metabolic disorders
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Glucagon-Like Peptide-1 is a natural hormone that regulates blood sugar, controls appetite, and slows digestion
Subscribe To Our Newsletter & Stay Updated
